- CA$137.65m
- CA$121.24m
- CA$35.03m
- 84
- 46
- 82
- 82
Annual balance sheet for Biosyent, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 25.6 | 28.2 | 28.7 | 26.2 | 15.9 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1.82 | 3.21 | 3.66 | 3.55 | 2.99 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 29.8 | 34.1 | 37.1 | 35.9 | 24.5 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2.16 | 1.93 | 1.67 | 1.44 | 1.2 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 33.6 | 37.2 | 40.5 | 41.5 | 41.4 |
| Payable / Accrued | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 5.14 | 4.14 | 5.72 | 5.53 | 5.41 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Liabilities | 6.78 | 5.61 | 7.12 | 6.77 | 6.36 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 26.8 | 31.6 | 33.4 | 34.8 | 35 |
| Total Liabilities & Shareholders' Equity | 33.6 | 37.2 | 40.5 | 41.5 | 41.4 |
| Total Common Shares Outstanding |